Pelthos Therapeutics Inc

Pelthos Therapeutics Inc has a market capitalization of $92.91 million and a price-to-book ratio of 2.39, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by $17.97 million in cash and equivalents, but it also has $31.44 million in long-term debt, resulting in a debt-to-equity ratio of 0.81. The company's free cash flow is negative at -$49.03 million, which suggests that it is not generating sufficient cash from operations to fund its capital expenditures and other operational needs. In terms of profitability, Pelthos Therapeutics Inc is currently unprofitable, with a net income of -$43.32 million and an operating income of -$32.72 million. The company's return on equity is -1.11, and its return on assets is -0.33, both of which are significantly below the industry median for biotechnology firms. These metrics indicate that the company is not effectively utilizing its equity and assets to generate profits. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher risk if its primary market or product line experiences a downturn. Looking at the company's growth trajectory, the current fiscal year is expected to show a negative revenue trend, with no specific numeric delta provided. The next fiscal year's outlook is also not quantified, but the company's negative operating and net income suggest that it is in a growth phase that is not yet profitable. The company's capital expenditures of -$7.99 million indicate ongoing investment in its operations, which may be necessary to support future growth. The risk assessment for Pelthos Therapeutics Inc indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag that could impact its ability to meet short-term obligations. The dilution risk is considered low, but the company's negative free cash flow and high capital expenditures may necessitate additional financing, which could lead to share dilution. Recent events and filings do not provide specific details on the company's operations or strategic initiatives, but the analyst estimates suggest a positive outlook from the investment community. The mean price target of $57.14 and the median price target of $55.00 indicate that analysts expect the stock to appreciate significantly from its current market price of $27.69. The mean recommendation of 1.86, with six buy ratings and one strong-buy rating, further supports this positive sentiment.